Literature DB >> 32374409

Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716.

Carl D Richards1, Rohan Gandhi, Fernando Botelho, Lilian Ho, John F Paolini.   

Abstract

To evaluate cellular response to oncostatin M (OSM) in comparison to interleukin (IL)-31, we analyzed monocyte chemoattractant protein 1 (MCP-1) as a readout for OSM responses with and without IL-4, IL-13, anti-OSM receptor β monoclonal antibody KPL-716, and anti-IL-31 receptor α antibody in human epidermal keratinocytes and human dermal fibroblasts in vitro. In human epidermal keratinocytes, OSM significantly induced STAT3 or STAT1 phosphorylation and synergized with IL-13 or IL-4 in elevating MCP-1. In human dermal fibroblasts, OSM results were similar, and leukemia inhibitory factor or IL-31 minimally activated STAT3 but not MCP-1. OSM significantly stimulated mRNA for type II IL-4 receptor and type II OSM receptor. KPL-716, not anti-IL-31Rα, significantly attenuated MCP-1 response to OSM and OSM + IL-4 in human epidermal keratinocytes and human dermal fibroblasts. OSM, not leukemia inhibitory factor or IL-31, synergized with IL-4 and IL-13 in human epidermal keratinocytes and human dermal fibroblasts, suggesting therapeutic potential of KPL-716 in inflammatory dermatologic diseases distinct from IL-31 inhibition.

Entities:  

Keywords:  inflammatory skin diseases; interleukins; keratinocytes; signaling; pruritus

Mesh:

Substances:

Year:  2020        PMID: 32374409      PMCID: PMC9199921          DOI: 10.2340/00015555-3505

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  34 in total

1.  Oncostatin M (OSM) primes IL-13- and IL-4-induced eotaxin responses in fibroblasts: regulation of the type-II IL-4 receptor chains IL-4Ralpha and IL-13Ralpha1.

Authors:  Dominik K Fritz; Christine Kerr; Fernando Botelho; Martin Stampfli; Carl D Richards
Journal:  Exp Cell Res       Date:  2009-09-30       Impact factor: 3.905

2.  A characteristic subset of psoriasis-associated genes is induced by oncostatin-M in reconstituted epidermis.

Authors:  Alix Gazel; Martin Rosdy; Béatrice Bertino; Carine Tornier; Florent Sahuc; Miroslav Blumenberg
Journal:  J Invest Dermatol       Date:  2006-08-17       Impact factor: 8.551

3.  Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms.

Authors:  F Blanchard; Y Wang; E Kinzie; L Duplomb; A Godard; H Baumann
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

4.  Oncostatin M overexpression induces skin inflammation but is not required in the mouse model of imiquimod-induced psoriasis-like inflammation.

Authors:  Mathilde Pohin; William Guesdon; Adela Andrine Tagne Mekouo; Hanitriniaina Rabeony; Isabelle Paris; Hristo Atanassov; Laure Favot; Jiad Mcheik; François-Xavier Bernard; Carl D Richards; Jérôme Amiaud; Frédéric Blanchard; Jean-Claude Lecron; Franck Morel; Jean-François Jégou
Journal:  Eur J Immunol       Date:  2016-05-12       Impact factor: 5.532

5.  Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.

Authors:  Stacey R Dillon; Cindy Sprecher; Angela Hammond; Janine Bilsborough; Maryland Rosenfeld-Franklin; Scott R Presnell; Harald S Haugen; Mark Maurer; Brandon Harder; Janet Johnston; Susan Bort; Sherri Mudri; Joseph L Kuijper; Tom Bukowski; Pamela Shea; Dennis L Dong; Maria Dasovich; Francis J Grant; Luann Lockwood; Steven D Levin; Cosette LeCiel; Kim Waggie; Heather Day; Stavros Topouzis; Janet Kramer; Rolf Kuestner; Zhi Chen; Don Foster; Julia Parrish-Novak; Jane A Gross
Journal:  Nat Immunol       Date:  2004-06-06       Impact factor: 25.606

6.  Oncostatin M stimulates proliferation, induces collagen production and inhibits apoptosis of human lung fibroblasts.

Authors:  Amelia K Scaffidi; Steven E Mutsaers; Yuben P Moodley; Robin J McAnulty; Geoffrey J Laurent; Philip J Thompson; Darryl A Knight
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

7.  IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis.

Authors:  Janine Bilsborough; Donald Y M Leung; Mark Maurer; Michael Howell; Mark Boguniewicz; Mark Boguniewcz; Lena Yao; Harold Storey; Cosette LeCiel; Brandon Harder; Jane A Gross
Journal:  J Allergy Clin Immunol       Date:  2006-02       Impact factor: 10.793

8.  Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody.

Authors:  Sohei Oyama; Hidetomo Kitamura; Taichi Kuramochi; Yoshinobu Higuchi; Hiroaki Matsushita; Tsukasa Suzuki; Masaaki Goto; Hideki Adachi; Keiko Kasutani; Akihisa Sakamoto; Yuki Iwayanagi; Akihisa Kaneko; Masahiko Nanami; Etsuko Fujii; Keiko Esaki; Yoshiaki Takashima; Shin Shimaoka; Kunihiro Hattori; Yoshiki Kawabe
Journal:  Exp Dermatol       Date:  2017-04-10       Impact factor: 3.960

9.  Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.

Authors:  Stacey L Fossey; Misty D Bear; William C Kisseberth; Michael Pennell; Cheryl A London
Journal:  BMC Cancer       Date:  2011-04-11       Impact factor: 4.430

10.  Regulation of IL-17A responses in human airway smooth muscle cells by Oncostatin M.

Authors:  Karen Kwofie; Matthew Scott; Rebecca Rodrigues; Jessica Guerette; Katherine Radford; Parameswaran Nair; Carl D Richards
Journal:  Respir Res       Date:  2015-02-07
View more
  2 in total

Review 1.  The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis.

Authors:  Lai-San Wong; Yu-Ta Yen; Chih-Hung Lee
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

Review 2.  Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis.

Authors:  Jianghui Meng; Yanqing Li; Michael J M Fischer; Martin Steinhoff; Weiwei Chen; Jiafu Wang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.